[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112022016382A2 - Triptaminas específicas para o uso no tratamento de doenças do humor - Google Patents

Triptaminas específicas para o uso no tratamento de doenças do humor

Info

Publication number
BR112022016382A2
BR112022016382A2 BR112022016382A BR112022016382A BR112022016382A2 BR 112022016382 A2 BR112022016382 A2 BR 112022016382A2 BR 112022016382 A BR112022016382 A BR 112022016382A BR 112022016382 A BR112022016382 A BR 112022016382A BR 112022016382 A2 BR112022016382 A2 BR 112022016382A2
Authority
BR
Brazil
Prior art keywords
triptamines
treatment
specific
mood
diseases
Prior art date
Application number
BR112022016382A
Other languages
English (en)
Inventor
Carry Kruegel Andrew
Sporn Jonathan
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Publication of BR112022016382A2 publication Critical patent/BR112022016382A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para tratar doenças do humor com os compostos divulgados neste documento. Também são fornecidas composições farmacêuticas que incluem esses compostos.
BR112022016382A 2020-02-18 2021-02-18 Triptaminas específicas para o uso no tratamento de doenças do humor BR112022016382A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978075P 2020-02-18 2020-02-18
PCT/US2021/018534 WO2021168082A1 (en) 2020-02-18 2021-02-18 Specific tryptamines for use in the treatment of mood disorders

Publications (1)

Publication Number Publication Date
BR112022016382A2 true BR112022016382A2 (pt) 2022-10-25

Family

ID=74871827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016382A BR112022016382A2 (pt) 2020-02-18 2021-02-18 Triptaminas específicas para o uso no tratamento de doenças do humor

Country Status (11)

Country Link
US (4) US20220241243A1 (pt)
EP (1) EP4084791A1 (pt)
JP (2) JP7242969B2 (pt)
KR (2) KR102567903B1 (pt)
CN (2) CN117503759A (pt)
AU (1) AU2021224899A1 (pt)
BR (1) BR112022016382A2 (pt)
CA (1) CA3172046A1 (pt)
IL (2) IL301235A (pt)
MX (2) MX2022010082A (pt)
WO (1) WO2021168082A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
JP2023526856A (ja) 2020-05-19 2023-06-23 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
CN116348106A (zh) 2020-09-01 2023-06-27 恩维瑞克生物科学加拿大公司 卤代裸盖菇素衍生物及使用方法
EP4347559A1 (en) * 2021-06-02 2024-04-10 Saint Joseph's University Fluorinated tryptamine compounds, analogues thereof, and methods using same
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
CN118696029A (zh) * 2021-12-24 2024-09-24 普赛洛私人有限公司 化合物
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt
AU2023244449A1 (en) * 2022-03-27 2024-11-07 GH Research Ireland Limited 5-meo-dtm for the treatment of bipolar disorder
WO2024046837A1 (en) * 2022-08-31 2024-03-07 Cybin Irl Limited Tryptamine compounds, compositions, and methods of use
WO2024108195A1 (en) * 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de) 1967-09-19 1971-07-22 Parke Davis & Co 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
US7297711B2 (en) 2002-06-21 2007-11-20 Suven Life Sciences Limited Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
DE60317333T2 (de) 2002-06-21 2008-08-28 Suven Life Sciences Ltd. Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
CA2490002C (en) 2002-06-21 2009-07-07 Suven Life Sciences Limited Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2009504597A (ja) 2005-08-10 2009-02-05 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト アシルトリプトファノール
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
JP5599774B2 (ja) 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ヒドロキシメチルシクロヘキシルアミン類
KR20110110297A (ko) 2009-01-09 2011-10-06 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 불소 함유 화합물 및 이의 사용방법
JP2012528120A (ja) 2009-05-27 2012-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル ミエロペルオキシダーゼ阻害３−アルキル−５−フルオロインドール誘導体
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20200030309A1 (en) 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7273731B2 (ja) * 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
KR102104953B1 (ko) 2018-04-17 2020-04-27 삼육대학교 산학협력단 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
WO2020181194A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
EP4081301A1 (en) 2019-12-26 2022-11-02 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
CN116348106A (zh) * 2020-09-01 2023-06-27 恩维瑞克生物科学加拿大公司 卤代裸盖菇素衍生物及使用方法
CN112174851A (zh) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Also Published As

Publication number Publication date
IL301235A (en) 2023-05-01
US20240317683A1 (en) 2024-09-26
CN117503759A (zh) 2024-02-06
JP7242969B2 (ja) 2023-03-20
JP2023063360A (ja) 2023-05-09
MX2024006123A (es) 2024-06-04
EP4084791A1 (en) 2022-11-09
WO2021168082A1 (en) 2021-08-26
IL295536A (en) 2022-10-01
US20240351983A1 (en) 2024-10-24
CN115135320A (zh) 2022-09-30
AU2021224899A1 (en) 2022-08-25
IL295536B1 (en) 2023-04-01
US20220241243A1 (en) 2022-08-04
IL295536B2 (en) 2023-08-01
KR20230124103A (ko) 2023-08-24
MX2022010082A (es) 2022-11-14
CA3172046A1 (en) 2021-08-26
KR102567903B1 (ko) 2023-08-18
KR20220129054A (ko) 2022-09-22
US11440879B2 (en) 2022-09-13
CN115135320B (zh) 2023-08-29
JP2023504308A (ja) 2023-02-02
US20220041551A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112022007612A2 (pt) Inibidores de raf quinases
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018007358A2 (pt) derivados de 1,4-dicarbonil-piperidila
CL2021000282A1 (es) Inhibidores de ckd8/19
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000749-2 PROTOCOLO 870230003856 EM 13/01/2023 17:05.